Compare WHD & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WHD | IDYA |
|---|---|---|
| Founded | 2011 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.9B |
| IPO Year | 2018 | 2019 |
| Metric | WHD | IDYA |
|---|---|---|
| Price | $44.54 | $33.91 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 14 |
| Target Price | $47.75 | ★ $49.42 |
| AVG Volume (30 Days) | 565.8K | ★ 850.2K |
| Earning Date | 10-29-2025 | 11-04-2025 |
| Dividend Yield | ★ 1.26% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.52 | N/A |
| Revenue | ★ $1,089,969,000.00 | $214,834,000.00 |
| Revenue This Year | N/A | $2,434.86 |
| Revenue Next Year | $29.89 | N/A |
| P/E Ratio | $17.61 | ★ N/A |
| Revenue Growth | N/A | ★ 5377.66 |
| 52 Week Low | $33.20 | $13.45 |
| 52 Week High | $68.90 | $36.55 |
| Indicator | WHD | IDYA |
|---|---|---|
| Relative Strength Index (RSI) | 66.46 | 58.37 |
| Support Level | $39.27 | $32.50 |
| Resistance Level | $43.46 | $36.55 |
| Average True Range (ATR) | 1.76 | 1.47 |
| MACD | 0.19 | -0.01 |
| Stochastic Oscillator | 99.09 | 50.19 |
Cactus Inc is engaged in the designing, manufacturing, and sale of wellheads and pressure control equipment. Its principal products include Cactus SafeDrill wellhead systems, conventional wellheads, and production valves among others. The company also provides mission-critical field services, including service crews to assist with the installation, maintenance, and safe handling of the wellhead and pressure control equipment, as well as repair services for equipment that it sells or rents. It sells or rents its products principally for onshore unconventional oil and gas wells that are utilized during the drilling, completion (including fracturing), and production. The company has two operating segments; Pressure Control, which generates key revenue and Spoolable Technologies.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.